Fig. 1 · Structure

Documents & Downloads

TG101209

Cat. No. A11180 CAS 936091-14-4

JAK2 inhibitor

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
JAK2 (Cell-free assay) 6 nM
RET (Cell-free assay) 17 nM
FLT3 (Cell-free assay) 25 nM
JAK3 (Cell-free assay) 169 nM

TG101209 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of TG101209 from 3 published references. In vitro models include Ba/F3-BCR-JAK2 cells; RAW264.7 macrophages. In vivo models include nude mice bearing Ramos-derived tumor xenografts.

TG101209 In Vitro Studies

In Ba/F3-BCR-JAK2 cells carrying pLZR with BCR-JAK2, TG101209 at 1 µM produced a 76% inhibition rate of BCR-JAK2 phosphorylation at 12 h compared with the vehicle (DMSO). In the same cell model carrying pLZR with BCR-JAK2, treatment at 1 µM for 24 h increased Annexin-V/7-AAD–positive cells by approximately 80% compared with DMSO. In RAW264.7 macrophages, TG101209 exhibited no significant cytotoxicity at concentrations below 5 μM within 24 hours. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

BCR-JAK2 phosphorylation inhibition in Ba/F3-BCR-JAK2 cells

Cell-based study · Ba/F3-BCR-JAK2 cells [1]

In Ba/F3-BCR-JAK2 cells carrying pLZR with BCR-JAK2, treatment at 1 µM for 12 h produced a 76% inhibition rate of BCR-JAK2 phosphorylation compared with the vehicle (DMSO).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BCR-JAK2 phosphorylationBCR-JAK2 phosphorylation 76% inhibition rate[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
12 h
Vehicle
DMSO
Co-treatment
Other interventions in this design: pLZR carrying BCR-JAK2. Compound effect isolated by the comparison: the vehicle (DMSO).
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: TG101209

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > TG101209 abrogated BCR-JAK2 activation and STAT5 phosphorylation leading to downregulation of STAT5 target gene transcription (S113, S115); Figure 2 legend (S165); Figure 4 legend (S185, S186)

BCR-JAK2 phosphorylation: BCR-JAK2 phosphorylation; comparator: the vehicle (DMSO) — Results > TG101209 abrogated BCR-JAK2 activation and STAT5 phosphorylation leading to downregulation of STAT5 target gene transcription (S113)

Cytotoxicity assessment in RAW264.7 macrophages

Cell-based study · RAW264.7 macrophages [2]

In RAW264.7 macrophages, TG101209 exhibited no significant cytotoxicity at concentrations below 5 μM within 24 hours.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cytotoxicityReported result TG101209 exhibited no significant cytotoxicity at concentrations below 5 μM within 24 hours[2]

Literature-Reported Treatment Conditions

Treatment concentration
below 5 μM
Exposure duration
within 24 hours
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: TG101209

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > TG101209 regulates macrophage polarization in vitro (S25, S26); Materials and methods > Cell viability assay (S54)

cytotoxicity: cytotoxicity; comparator: control optical density — Results > TG101209 regulates macrophage polarization in vitro (S26)

Increased annexin-positive cells in Ba/F3-BCR-JAK2 cultures

Cell-based study · Ba/F3-BCR-JAK2 cells [1]

In Ba/F3-BCR-JAK2 cells carrying pLZR with BCR-JAK2, treatment at 1 µM for 24 h increased Annexin-V/7-AAD–positive cells by approximately 80% compared with DMSO.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apoptosis was measured using flow cytometry analysis as the percentage of cells expressing annexin-V/7-AAD on the cell surface.Annexin-V/7-AAD–positive cells increase of approximately 80%[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
24 h
Vehicle
DMSO
Co-treatment
Other interventions in this design: pLZR carrying BCR-JAK2. Compound effect isolated by the comparison: DMSO.
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: TG101209

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Apoptosis analysis by flow cytometry (S63); Results > TG101209 induces Ba/F3-BCR-JAK2 cell death by apoptosis (S123); Figure 2 legend (S165); Figure 5 legend (S195, S197)

Apoptosis was measured using flow cytometry analysis as the percentage of cells expressing annexin-V/7-AAD on the cell surface.: Apoptosis was measured using flow cytometry analysis as the percentage of cells expressing annexin-V/7-AAD on the cell surface.; comparator: DMSO — Results > TG101209 induces Ba/F3-BCR-JAK2 cell death by apoptosis (S123); Figure 5 legend (S197)

TG101209 In Vivo Studies

Nude mice bearing Ramos-derived tumor xenografts received TG101209 by oral gavage at 100 mg/kg BID for 7 consecutive days. TG101209 significantly suppressed tumor xenograft growth compared with the control group receiving DMSO only. [3]

Tumor xenograft growth suppression in nude mice

Animal study · nude mice bearing Ramos-derived tumor xenografts [3]

In nude mice bearing Ramos-derived tumor xenografts, TG101209 orally gavaged at 100 mg/kg BID for 7 consecutive days significantly suppressed tumor xenograft growth compared with the control group receiving DMSO only.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volumeReported result TG101209 significantly suppressed the growth of tumor xenografts[3]

Conditions shared by the study groups

Route
orally gavaged
Treatment course
BID for 7 consecutive days
Vehicle
DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
TG101209 100 mg/kgthe control group received DMSO onlyTG101209 significantly suppressed the growth of tumor xenografts[3]
TG101209 100 mg/kg
Model: nude mice bearing Ramos-derived tumor xenografts
Methods and source locations

Compound reported in the paper: TG101209

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Ramos-derived xenograft mouse model (S94); Fig. 6 legend (S155, S156)

Tumor volume: Tumor volume; comparator: the control group received DMSO only — Fig. 6 legend (S156)

TG101209 100 mg/kg · Fig. 6 legend (S155, S156)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 936091-14-4
Applications JAK2 inhibitor
Formula C26H35N7O2S
Molecular Weight 509.67
SMILES
CN1CCN(CC1)C2=CC=C(C=C2)NC3N=C(NC4=CC(=CC=C4)S(=O)(=O)NC(C)(C)C)C(C)=CN=3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 94 mg/mL (184.42 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
11 mg/mL
Vehicle
1% DMSO+30% polyethylene glycol+1% Tween 80

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

TG101209 Research References

  1. [1] Cuesta-Domínguez Á, Ortega M, Ormazábal C, et al. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. PLoS One (2012). PMID: 22384256 DOI: 10.1371/journal.pone.0032451 Source material
  2. [2] Ye J, Pan Y, Jia C, et al. Selective JAK2 inhibition by TG101209 reprograms macrophage polarization and alleviates acute lung injury. Front Immunol (2026). PMID: 41909672 DOI: 10.3389/fimmu.2026.1755208 Source material
  3. [3] Zhang Y, Li J, Zhong H, et al. The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis. Cell Death Discov (2021). PMID: 34588425 DOI: 10.1038/s41420-021-00655-1 Source material

Added to your cart

View Cart Checkout
Loading...